Global Valsartan Tablets Market

Valsartan Tablets Comprehensive Study by Application (Hypertension, Heart Failure, Heart Attack), Category (Adult, Pediatric), Dose (40mg, 80mg, 160mg, 320mg), End-user (Hospital, Clinic, Recovery Centre) Players and Region - Global Market Outlook to 2026

Valsartan Tablets Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Valsartan Tablets?
Valsartan is a medicine which commonly used to treat high blood pressure and heart failure. It's also sometimes recommended after a heart attack. It comes in form of tablets, capsules and as a liquid that you swallow. Valsartan belongs to a class of drugs known as angiotensin receptor blockers. Valsartan also presented in generic drugs.

The market study is broken down, by Application (Hypertension, Heart Failure and Heart Attack) and major geographies with country level break-up.

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Analysts at AMA Research estimates that Players from Indians will contribute to the maximum growth of Global Valsartan Tablets market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Alembic (India), Cadista (Maryland), Camber (United States), Mylan (United States), Solco Healthcare (United States), Hetero (India), Teva (Israel), Lupin (India), Aurobindo (India), Zhejiang Huahai Pharm (Linhai) and Novartis (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Ranbaxy (India).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Valsartan Tablets market by Type, Application and Region.

On the basis of geography, the market of Valsartan Tablets has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Category , the sub-segment i.e. Adult will boost the Valsartan Tablets market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Dose, the sub-segment i.e. 40mg will boost the Valsartan Tablets market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-user, the sub-segment i.e. Hospital will boost the Valsartan Tablets market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.


In 2019, FDA approves a new generic valsartan. Approval of these new generic of Diovan was granted to Alkem Laboratories Limited. Alkem laboratories also developed new tests to check for the contaminants.

Market Trend
  • New varieties of tablets are developing

Market Drivers
  • Increasing patient of heart attack increases demand for tablets

Opportunities
  • Rising Government Investment in tablets

Restraints
  • Lack of awareness of tablets

Challenges
  • High cost associated with tablet


Key Target Audience
Manufacturers, Distributors, Supplier of Valsartan Tablets, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Application
  • Hypertension
  • Heart Failure
  • Heart Attack
By Category
  • Adult
  • Pediatric

By Dose
  • 40mg
  • 80mg
  • 160mg
  • 320mg

By End-user
  • Hospital
  • Clinic
  • Recovery Centre

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing patient of heart attack increases demand for tablets
    • 3.3. Market Challenges
      • 3.3.1. High cost associated with tablet
    • 3.4. Market Trends
      • 3.4.1. New varieties of tablets are developing
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Valsartan Tablets, by Application, Category , Dose, End-user and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Valsartan Tablets (Value)
      • 5.2.1. Global Valsartan Tablets by: Application (Value)
        • 5.2.1.1. Hypertension
        • 5.2.1.2. Heart Failure
        • 5.2.1.3. Heart Attack
      • 5.2.2. Global Valsartan Tablets by: Dose (Value)
        • 5.2.2.1. 40mg
        • 5.2.2.2. 80mg
        • 5.2.2.3. 160mg
        • 5.2.2.4. 320mg
      • 5.2.3. Global Valsartan Tablets Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Australia
          • 5.2.3.2.6. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Valsartan Tablets (Volume)
      • 5.3.1. Global Valsartan Tablets by: Application (Volume)
        • 5.3.1.1. Hypertension
        • 5.3.1.2. Heart Failure
        • 5.3.1.3. Heart Attack
      • 5.3.2. Global Valsartan Tablets by: Dose (Volume)
        • 5.3.2.1. 40mg
        • 5.3.2.2. 80mg
        • 5.3.2.3. 160mg
        • 5.3.2.4. 320mg
      • 5.3.3. Global Valsartan Tablets Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Australia
          • 5.3.3.2.6. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Valsartan Tablets (Price)
  • 6. Valsartan Tablets: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Alembic (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Cadista (Maryland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Camber (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mylan (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Solco Healthcare (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Hetero (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Teva (Israel)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Lupin (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Aurobindo (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Zhejiang Huahai Pharm (Linhai)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Novartis (Switzerland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Valsartan Tablets Sale, by Application, Category , Dose, End-user and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Valsartan Tablets (Value)
      • 7.2.1. Global Valsartan Tablets by: Application (Value)
        • 7.2.1.1. Hypertension
        • 7.2.1.2. Heart Failure
        • 7.2.1.3. Heart Attack
      • 7.2.2. Global Valsartan Tablets by: Dose (Value)
        • 7.2.2.1. 40mg
        • 7.2.2.2. 80mg
        • 7.2.2.3. 160mg
        • 7.2.2.4. 320mg
      • 7.2.3. Global Valsartan Tablets Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Australia
          • 7.2.3.2.6. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Valsartan Tablets (Volume)
      • 7.3.1. Global Valsartan Tablets by: Application (Volume)
        • 7.3.1.1. Hypertension
        • 7.3.1.2. Heart Failure
        • 7.3.1.3. Heart Attack
      • 7.3.2. Global Valsartan Tablets by: Dose (Volume)
        • 7.3.2.1. 40mg
        • 7.3.2.2. 80mg
        • 7.3.2.3. 160mg
        • 7.3.2.4. 320mg
      • 7.3.3. Global Valsartan Tablets Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Australia
          • 7.3.3.2.6. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Valsartan Tablets (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Valsartan Tablets: by Application(USD Million)
  • Figure 4. Global Valsartan Tablets: by Application USD Million (2015-2020)
  • Table 2. Valsartan Tablets Hypertension , by Region USD Million (2015-2020)
  • Table 3. Valsartan Tablets Heart Failure , by Region USD Million (2015-2020)
  • Table 4. Valsartan Tablets Heart Attack , by Region USD Million (2015-2020)
  • Table 5. Valsartan Tablets: by Dose(USD Million)
  • Figure 5. Global Valsartan Tablets: by Dose USD Million (2015-2020)
  • Table 6. Valsartan Tablets 40mg , by Region USD Million (2015-2020)
  • Table 7. Valsartan Tablets 80mg , by Region USD Million (2015-2020)
  • Table 8. Valsartan Tablets 160mg , by Region USD Million (2015-2020)
  • Table 9. Valsartan Tablets 320mg , by Region USD Million (2015-2020)
  • Table 10. South America Valsartan Tablets, by Country USD Million (2015-2020)
  • Figure 6. South America Valsartan Tablets Share (%), by Country
  • Table 11. South America Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 12. South America Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 13. South America Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 14. South America Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 15. Brazil Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 16. Brazil Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 17. Brazil Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 18. Brazil Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 19. Argentina Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 20. Argentina Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 21. Argentina Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 22. Argentina Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 23. Rest of South America Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 24. Rest of South America Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 25. Rest of South America Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 26. Rest of South America Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 27. Asia Pacific Valsartan Tablets, by Country USD Million (2015-2020)
  • Figure 7. Asia Pacific Valsartan Tablets Share (%), by Country
  • Table 28. Asia Pacific Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 29. Asia Pacific Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 30. Asia Pacific Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 31. Asia Pacific Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 32. China Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 33. China Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 34. China Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 35. China Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 36. Japan Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 37. Japan Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 38. Japan Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 39. Japan Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 40. India Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 41. India Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 42. India Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 43. India Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 44. South Korea Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 45. South Korea Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 46. South Korea Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 47. South Korea Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 48. Australia Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 49. Australia Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 50. Australia Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 51. Australia Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 55. Rest of Asia-Pacific Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 56. Europe Valsartan Tablets, by Country USD Million (2015-2020)
  • Figure 8. Europe Valsartan Tablets Share (%), by Country
  • Table 57. Europe Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 58. Europe Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 59. Europe Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 60. Europe Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 61. Germany Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 62. Germany Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 63. Germany Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 64. Germany Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 65. France Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 66. France Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 67. France Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 68. France Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 69. Italy Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 70. Italy Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 71. Italy Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 72. Italy Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 73. United Kingdom Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 74. United Kingdom Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 75. United Kingdom Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 76. United Kingdom Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 77. Netherlands Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 78. Netherlands Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 79. Netherlands Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 80. Netherlands Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 81. Rest of Europe Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 82. Rest of Europe Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 83. Rest of Europe Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 84. Rest of Europe Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 85. MEA Valsartan Tablets, by Country USD Million (2015-2020)
  • Figure 9. MEA Valsartan Tablets Share (%), by Country
  • Table 86. MEA Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 87. MEA Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 88. MEA Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 89. MEA Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 90. Middle East Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 91. Middle East Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 92. Middle East Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 93. Middle East Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 94. Africa Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 95. Africa Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 96. Africa Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 97. Africa Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 98. North America Valsartan Tablets, by Country USD Million (2015-2020)
  • Figure 10. North America Valsartan Tablets Share (%), by Country
  • Table 99. North America Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 100. North America Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 101. North America Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 102. North America Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 103. United States Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 104. United States Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 105. United States Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 106. United States Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 107. Canada Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 108. Canada Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 109. Canada Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 110. Canada Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 111. Mexico Valsartan Tablets, by Application USD Million (2015-2020)
  • Table 112. Mexico Valsartan Tablets, by Category USD Million (2015-2020)
  • Table 113. Mexico Valsartan Tablets, by Dose USD Million (2015-2020)
  • Table 114. Mexico Valsartan Tablets, by End-user USD Million (2015-2020)
  • Table 115. Valsartan Tablets Sales: by Application(K Units)
  • Figure 11. Global Valsartan Tablets: by Application K Units (2015-2020)
  • Table 116. Valsartan Tablets Sales Hypertension , by Region K Units (2015-2020)
  • Table 117. Valsartan Tablets Sales Heart Failure , by Region K Units (2015-2020)
  • Table 118. Valsartan Tablets Sales Heart Attack , by Region K Units (2015-2020)
  • Table 119. Valsartan Tablets Sales: by Dose(K Units)
  • Figure 12. Global Valsartan Tablets: by Dose K Units (2015-2020)
  • Table 120. Valsartan Tablets Sales 40mg , by Region K Units (2015-2020)
  • Table 121. Valsartan Tablets Sales 80mg , by Region K Units (2015-2020)
  • Table 122. Valsartan Tablets Sales 160mg , by Region K Units (2015-2020)
  • Table 123. Valsartan Tablets Sales 320mg , by Region K Units (2015-2020)
  • Table 124. South America Valsartan Tablets Sales, by Country K Units (2015-2020)
  • Figure 13. South America Valsartan Tablets Share (%), by Country
  • Table 125. South America Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 126. South America Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 127. South America Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 128. South America Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 129. Brazil Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 130. Brazil Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 131. Brazil Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 132. Brazil Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 133. Argentina Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 134. Argentina Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 135. Argentina Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 136. Argentina Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 137. Rest of South America Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 138. Rest of South America Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 139. Rest of South America Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 140. Rest of South America Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 141. Asia Pacific Valsartan Tablets Sales, by Country K Units (2015-2020)
  • Figure 14. Asia Pacific Valsartan Tablets Share (%), by Country
  • Table 142. Asia Pacific Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 143. Asia Pacific Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 144. Asia Pacific Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 145. Asia Pacific Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 146. China Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 147. China Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 148. China Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 149. China Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 150. Japan Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 151. Japan Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 152. Japan Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 153. Japan Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 154. India Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 155. India Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 156. India Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 157. India Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 158. South Korea Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 159. South Korea Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 160. South Korea Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 161. South Korea Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 162. Australia Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 163. Australia Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 164. Australia Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 165. Australia Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 166. Rest of Asia-Pacific Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 167. Rest of Asia-Pacific Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 168. Rest of Asia-Pacific Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 169. Rest of Asia-Pacific Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 170. Europe Valsartan Tablets Sales, by Country K Units (2015-2020)
  • Figure 15. Europe Valsartan Tablets Share (%), by Country
  • Table 171. Europe Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 172. Europe Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 173. Europe Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 174. Europe Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 175. Germany Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 176. Germany Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 177. Germany Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 178. Germany Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 179. France Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 180. France Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 181. France Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 182. France Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 183. Italy Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 184. Italy Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 185. Italy Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 186. Italy Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 187. United Kingdom Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 188. United Kingdom Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 189. United Kingdom Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 190. United Kingdom Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 191. Netherlands Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 192. Netherlands Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 193. Netherlands Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 194. Netherlands Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 195. Rest of Europe Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 196. Rest of Europe Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 197. Rest of Europe Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 198. Rest of Europe Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 199. MEA Valsartan Tablets Sales, by Country K Units (2015-2020)
  • Figure 16. MEA Valsartan Tablets Share (%), by Country
  • Table 200. MEA Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 201. MEA Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 202. MEA Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 203. MEA Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 204. Middle East Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 205. Middle East Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 206. Middle East Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 207. Middle East Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 208. Africa Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 209. Africa Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 210. Africa Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 211. Africa Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 212. North America Valsartan Tablets Sales, by Country K Units (2015-2020)
  • Figure 17. North America Valsartan Tablets Share (%), by Country
  • Table 213. North America Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 214. North America Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 215. North America Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 216. North America Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 217. United States Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 218. United States Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 219. United States Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 220. United States Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 221. Canada Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 222. Canada Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 223. Canada Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 224. Canada Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Table 225. Mexico Valsartan Tablets Sales, by Application K Units (2015-2020)
  • Table 226. Mexico Valsartan Tablets Sales, by Category K Units (2015-2020)
  • Table 227. Mexico Valsartan Tablets Sales, by Dose K Units (2015-2020)
  • Table 228. Mexico Valsartan Tablets Sales, by End-user K Units (2015-2020)
  • Figure 18. Global Valsartan Tablets share by Players 2020 (%)
  • Figure 19. Global Valsartan Tablets share by Players (Top 3) 2020(%)
  • Figure 20. Global Valsartan Tablets share by Players (Top 5) 2020(%)
  • Table 229. Company Basic Information, Sales Area and Its Competitors
  • Table 230. Company Basic Information, Sales Area and Its Competitors
  • Table 231. Company Basic Information, Sales Area and Its Competitors
  • Table 232. Company Basic Information, Sales Area and Its Competitors
  • Table 233. Company Basic Information, Sales Area and Its Competitors
  • Table 234. Company Basic Information, Sales Area and Its Competitors
  • Table 235. Company Basic Information, Sales Area and Its Competitors
  • Table 236. Company Basic Information, Sales Area and Its Competitors
  • Table 237. Company Basic Information, Sales Area and Its Competitors
  • Table 238. Company Basic Information, Sales Area and Its Competitors
  • Table 239. Company Basic Information, Sales Area and Its Competitors
  • Table 240. Valsartan Tablets: by Application(USD Million)
  • Figure 44. Global Valsartan Tablets: by Application USD Million (2021-2026)
  • Table 241. Valsartan Tablets Hypertension , by Region USD Million (2021-2026)
  • Table 242. Valsartan Tablets Heart Failure , by Region USD Million (2021-2026)
  • Table 243. Valsartan Tablets Heart Attack , by Region USD Million (2021-2026)
  • Table 244. Valsartan Tablets: by Dose(USD Million)
  • Figure 45. Global Valsartan Tablets: by Dose USD Million (2021-2026)
  • Table 245. Valsartan Tablets 40mg , by Region USD Million (2021-2026)
  • Table 246. Valsartan Tablets 80mg , by Region USD Million (2021-2026)
  • Table 247. Valsartan Tablets 160mg , by Region USD Million (2021-2026)
  • Table 248. Valsartan Tablets 320mg , by Region USD Million (2021-2026)
  • Table 249. South America Valsartan Tablets, by Country USD Million (2021-2026)
  • Figure 46. South America Valsartan Tablets Share (%), by Country
  • Table 250. South America Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 251. South America Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 252. South America Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 253. South America Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 254. Brazil Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 255. Brazil Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 256. Brazil Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 257. Brazil Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 258. Argentina Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 259. Argentina Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 260. Argentina Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 261. Argentina Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 262. Rest of South America Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 263. Rest of South America Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 264. Rest of South America Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 265. Rest of South America Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 266. Asia Pacific Valsartan Tablets, by Country USD Million (2021-2026)
  • Figure 47. Asia Pacific Valsartan Tablets Share (%), by Country
  • Table 267. Asia Pacific Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 268. Asia Pacific Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 269. Asia Pacific Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 270. Asia Pacific Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 271. China Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 272. China Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 273. China Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 274. China Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 275. Japan Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 276. Japan Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 277. Japan Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 278. Japan Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 279. India Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 280. India Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 281. India Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 282. India Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 283. South Korea Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 284. South Korea Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 285. South Korea Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 286. South Korea Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 287. Australia Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 288. Australia Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 289. Australia Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 290. Australia Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 291. Rest of Asia-Pacific Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 292. Rest of Asia-Pacific Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 293. Rest of Asia-Pacific Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 294. Rest of Asia-Pacific Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 295. Europe Valsartan Tablets, by Country USD Million (2021-2026)
  • Figure 48. Europe Valsartan Tablets Share (%), by Country
  • Table 296. Europe Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 297. Europe Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 298. Europe Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 299. Europe Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 300. Germany Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 301. Germany Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 302. Germany Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 303. Germany Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 304. France Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 305. France Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 306. France Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 307. France Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 308. Italy Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 309. Italy Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 310. Italy Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 311. Italy Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 312. United Kingdom Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 313. United Kingdom Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 314. United Kingdom Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 315. United Kingdom Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 316. Netherlands Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 317. Netherlands Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 318. Netherlands Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 319. Netherlands Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 320. Rest of Europe Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 321. Rest of Europe Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 322. Rest of Europe Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 323. Rest of Europe Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 324. MEA Valsartan Tablets, by Country USD Million (2021-2026)
  • Figure 49. MEA Valsartan Tablets Share (%), by Country
  • Table 325. MEA Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 326. MEA Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 327. MEA Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 328. MEA Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 329. Middle East Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 330. Middle East Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 331. Middle East Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 332. Middle East Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 333. Africa Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 334. Africa Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 335. Africa Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 336. Africa Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 337. North America Valsartan Tablets, by Country USD Million (2021-2026)
  • Figure 50. North America Valsartan Tablets Share (%), by Country
  • Table 338. North America Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 339. North America Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 340. North America Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 341. North America Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 342. United States Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 343. United States Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 344. United States Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 345. United States Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 346. Canada Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 347. Canada Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 348. Canada Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 349. Canada Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 350. Mexico Valsartan Tablets, by Application USD Million (2021-2026)
  • Table 351. Mexico Valsartan Tablets, by Category USD Million (2021-2026)
  • Table 352. Mexico Valsartan Tablets, by Dose USD Million (2021-2026)
  • Table 353. Mexico Valsartan Tablets, by End-user USD Million (2021-2026)
  • Table 354. Valsartan Tablets Sales: by Application(K Units)
  • Figure 51. Global Valsartan Tablets: by Application K Units (2021-2026)
  • Table 355. Valsartan Tablets Sales Hypertension , by Region K Units (2021-2026)
  • Table 356. Valsartan Tablets Sales Heart Failure , by Region K Units (2021-2026)
  • Table 357. Valsartan Tablets Sales Heart Attack , by Region K Units (2021-2026)
  • Table 358. Valsartan Tablets Sales: by Dose(K Units)
  • Figure 52. Global Valsartan Tablets: by Dose K Units (2021-2026)
  • Table 359. Valsartan Tablets Sales 40mg , by Region K Units (2021-2026)
  • Table 360. Valsartan Tablets Sales 80mg , by Region K Units (2021-2026)
  • Table 361. Valsartan Tablets Sales 160mg , by Region K Units (2021-2026)
  • Table 362. Valsartan Tablets Sales 320mg , by Region K Units (2021-2026)
  • Table 363. South America Valsartan Tablets Sales, by Country K Units (2021-2026)
  • Figure 53. South America Valsartan Tablets Share (%), by Country
  • Table 364. South America Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 365. South America Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 366. South America Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 367. South America Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 368. Brazil Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 369. Brazil Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 370. Brazil Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 371. Brazil Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 372. Argentina Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 373. Argentina Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 374. Argentina Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 375. Argentina Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 376. Rest of South America Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 377. Rest of South America Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 378. Rest of South America Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 379. Rest of South America Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 380. Asia Pacific Valsartan Tablets Sales, by Country K Units (2021-2026)
  • Figure 54. Asia Pacific Valsartan Tablets Share (%), by Country
  • Table 381. Asia Pacific Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 382. Asia Pacific Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 383. Asia Pacific Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 384. Asia Pacific Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 385. China Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 386. China Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 387. China Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 388. China Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 389. Japan Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 390. Japan Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 391. Japan Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 392. Japan Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 393. India Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 394. India Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 395. India Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 396. India Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 397. South Korea Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 398. South Korea Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 399. South Korea Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 400. South Korea Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 401. Australia Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 402. Australia Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 403. Australia Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 404. Australia Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 405. Rest of Asia-Pacific Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 406. Rest of Asia-Pacific Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 407. Rest of Asia-Pacific Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 408. Rest of Asia-Pacific Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 409. Europe Valsartan Tablets Sales, by Country K Units (2021-2026)
  • Figure 55. Europe Valsartan Tablets Share (%), by Country
  • Table 410. Europe Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 411. Europe Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 412. Europe Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 413. Europe Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 414. Germany Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 415. Germany Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 416. Germany Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 417. Germany Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 418. France Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 419. France Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 420. France Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 421. France Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 422. Italy Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 423. Italy Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 424. Italy Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 425. Italy Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 426. United Kingdom Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 427. United Kingdom Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 428. United Kingdom Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 429. United Kingdom Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 430. Netherlands Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 431. Netherlands Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 432. Netherlands Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 433. Netherlands Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 434. Rest of Europe Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 435. Rest of Europe Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 436. Rest of Europe Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 437. Rest of Europe Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 438. MEA Valsartan Tablets Sales, by Country K Units (2021-2026)
  • Figure 56. MEA Valsartan Tablets Share (%), by Country
  • Table 439. MEA Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 440. MEA Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 441. MEA Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 442. MEA Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 443. Middle East Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 444. Middle East Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 445. Middle East Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 446. Middle East Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 447. Africa Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 448. Africa Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 449. Africa Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 450. Africa Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 451. North America Valsartan Tablets Sales, by Country K Units (2021-2026)
  • Figure 57. North America Valsartan Tablets Share (%), by Country
  • Table 452. North America Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 453. North America Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 454. North America Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 455. North America Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 456. United States Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 457. United States Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 458. United States Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 459. United States Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 460. Canada Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 461. Canada Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 462. Canada Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 463. Canada Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 464. Mexico Valsartan Tablets Sales, by Application K Units (2021-2026)
  • Table 465. Mexico Valsartan Tablets Sales, by Category K Units (2021-2026)
  • Table 466. Mexico Valsartan Tablets Sales, by Dose K Units (2021-2026)
  • Table 467. Mexico Valsartan Tablets Sales, by End-user K Units (2021-2026)
  • Table 468. Research Programs/Design for This Report
  • Table 469. Key Data Information from Secondary Sources
  • Table 470. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 21. BCG Matrix for key Companies
  • Figure 22. Alembic (India) Revenue, Net Income and Gross profit
  • Figure 23. Alembic (India) Revenue: by Geography 2020
  • Figure 24. Cadista (Maryland) Revenue, Net Income and Gross profit
  • Figure 25. Cadista (Maryland) Revenue: by Geography 2020
  • Figure 26. Camber (United States) Revenue, Net Income and Gross profit
  • Figure 27. Camber (United States) Revenue: by Geography 2020
  • Figure 28. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 29. Mylan (United States) Revenue: by Geography 2020
  • Figure 30. Solco Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 31. Solco Healthcare (United States) Revenue: by Geography 2020
  • Figure 32. Hetero (India) Revenue, Net Income and Gross profit
  • Figure 33. Hetero (India) Revenue: by Geography 2020
  • Figure 34. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 35. Teva (Israel) Revenue: by Geography 2020
  • Figure 36. Lupin (India) Revenue, Net Income and Gross profit
  • Figure 37. Lupin (India) Revenue: by Geography 2020
  • Figure 38. Aurobindo (India) Revenue, Net Income and Gross profit
  • Figure 39. Aurobindo (India) Revenue: by Geography 2020
  • Figure 40. Zhejiang Huahai Pharm (Linhai) Revenue, Net Income and Gross profit
  • Figure 41. Zhejiang Huahai Pharm (Linhai) Revenue: by Geography 2020
  • Figure 42. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 43. Novartis (Switzerland) Revenue: by Geography 2020
List of companies from research coverage that are profiled in the study
  • Alembic (India)
  • Cadista (Maryland)
  • Camber (United States)
  • Mylan (United States)
  • Solco Healthcare (United States)
  • Hetero (India)
  • Teva (Israel)
  • Lupin (India)
  • Aurobindo (India)
  • Zhejiang Huahai Pharm (Linhai)
  • Novartis (Switzerland)
Additional players considered in the study are as follows:
Ranbaxy (India)
Select User Access Type

Key Highlights of Report


Feb 2022 219 Pages 60 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Valsartan Tablets Market Quantitative research analysis
Global Valsartan Tablets Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Alembic (India), Cadista (Maryland), Camber (United States), Mylan (United States), Solco Healthcare (United States), Hetero (India), Teva (Israel), Lupin (India), Aurobindo (India), Zhejiang Huahai Pharm (Linhai) and Novartis (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
Analysts at AMA estimates Valsartan Tablets Market to reach USD Million by 2026.

Know More About Global Valsartan Tablets Market Report?

Have a Query? Click Here

Other Related Reports

At-home Saliva Testing Kit Comprehensive Study by Type (Test Strip, Cassette), Indication (Malaria, Ovulation, HIV, COVID, Others), Distribution Channel (Drugstores, Retail Pharmacies, Hospital Chain...
$ 3350
Viral Transport Kit Comprehensive Study by Type (Tissue Culture Medium, Glycerol Transport Medium), Application (Herpes Simplex Type I, Herpes Simplex Type II, Cytomegalovirus (CMV), Influenza A, Inf...
$ 3800
Human Rabies Treatment - Comprehensive Study by Type (Vero Cell Rabies Vaccine, BHK, Chick Embryo Cell Rabies Vaccine, Others), Application (Pre-Exposure Prophylaxis, Post-Exposure Prophylaxis), Dist...
$ 3450
Fibrate Drugs Comprehensive Study by Type (Gemfibrozil, Lofibrate, Fenofibric Acids, Fenofibrates), End users (Hospitals, Homecare, Specialty clinics, Others), Distribution Channel (Hospital pharmacy...
$ 3350
Portal Hypertension Drugs Comprehensive Study by Type (Prehepatic, Intrahepatic, Posthepatic), Treatment (Endoscopic Therapy, Surgery, Radiology, Others), Drug Class (Vasoconstrictors, Vasodilators, ...
$ 3450
Vaginitis Drug Comprehensive Study by Drugs (Nitro Imidazole Compounds, Lincosamide Antibiotics, Triazoles, Imidazoles), Schedule of Drug (Rx, OTC), Route of Adminstration (Oral, Cutaneous, Vaginal),...
$ 3650